RxDoctor Payments Data

Manju John

Cardiovascular Disease · Middletown, CTNPI 1194987313

Payments from drug & device makers

$402in general payments, 2019–2025

Across 22 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$71
  • Pfizer$57
  • Regeneron Healthcare Solutions, Inc.$42
  • Boehringer Ingelheim$39
  • Novartis$33
  • Amarin Pharma, Inc.$32
  • plus $128 from 7 others

What the payments were for

  • Food & beverage$38095%
  • Education$225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$402 in reported general payments places this provider in the 25th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$169,049
Medicare patients
1,008
Services billed
2,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban414$522,305
XareltoRivaroxaban282$301,697
EntrestoSacubitril/Valsartan44$57,018
Repatha SureclickEvolocumab58$56,817
VascepaIcosapent Ethyl72$27,244
Praluent PenAlirocumab37$21,413
JardianceEmpagliflozin16$18,877
Metoprolol Succinate1,076$15,620
BrilintaTicagrelor25$15,461
Icosapent Ethyl70$14,483
Diltiazem 24hr Er (Cd)Diltiazem Hcl188$8,086
Atorvastatin Calcium622$6,293
Rosuvastatin Calcium330$4,038
Ezetimibe213$3,675
Dofetilide22$3,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$522,305414 claims
NovartisEntresto$33$57,01844 claims
Boehringer IngelheimJardiance$39$18,87716 claims
AstraZenecaBrilinta$14$15,46125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →